Increased body fat mass reduces the association between fructosamine and HbA1c in obese type 2 diabetic patients.

Fiche publication

Date publication

août 2020

Journal

Journal of diabetes investigation

Auteurs

Membres identifiés du Cancéropôle Est :
Pr DUVILLARD Laurence , Pr PETIT Jean-Michel , Pr VERGES Bruno

Tous les auteurs :
Vergès B, Rouland A, Baillot-Rudoni S, Brindisi MC, Duvillard L, Simoneau I, Legris P, Petit JM, Bouillet B

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/32767822

Résumé

Obesity is increasing in patients with type 2 diabetes (T2D). A possible reduced association between fructosamine and HbA1c in obese individuals has been previously discussed, but this has never been specifically evaluated in T2D and the potential influence of body fat mass and fat distribution has never been studied. We studied 112 T2D patients with assessment of fat mass, liver fat and fat distribution. Patients with BMI above the median (34.9 kg/m ), versus BMI below the median, had a correlation coefficient between fructosamine and HbA1c significantly reduced (r=0.358 vs. r=0.765). In the whole population, fructosamine was correlated negatively with BMI and fat mass. In multivariate analysis, fructosamine was associated with HbA1c (positively) and fat mass (negatively) but not with BMI, liver fat or fat distribution. The association between fructosamine and HbA1c is significantly reduced in the most obese T2D patients and this is mostly driven by increased fat mass.